The U.S. government has pulled the rug out from under Pluri Biotech’s PLX-R18 cell therapy. | The U.S. government has pulled ...

Protalix BioTherapeutics is profitable with key pipeline momentum and strategic interest. Check out why PLX stock is a strong ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Protalix BioTherapeutics, Inc.’s PLX share price has surged by 8.71%, which has investors questioning if this is right time to sell.

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025. The Dow Jones closed lower by ...

RVPH Reviva Pharmaceuticals Holdings, Inc.